Dermatological collars for non-human animals

Abstract

The present invention relates to a collar for non-human animals, preferably companion animals, comprising a polymer matrix and a lipid extract comprising sphingomyelin.It also refers to a collar for use as a medicine, in particular a collar for use as an adjuvant, and a collar for use in treating or preventing atopic or allergic dermatitis, and a collar for use in restoring skin integrity during or after atopic or allergic dermatitis, increasing skin moisture and softness, promoting skin regeneration, or reducing skin itching.

Description

Technical Field

[0001] The present invention relates to a collar for non-human animals incorporating a lipid extract containing sphingomyelin. Also mentioned are collars for use as pharmaceuticals, particularly for use as adjuvants, and collars for use in the treatment or prevention of atopic dermatitis or allergic dermatitis, and collars for use in restoring skin integrity during or after atopic dermatitis or allergic dermatitis, increasing skin moisture and flexibility, promoting skin regeneration, or reducing skin itching.

Background Art

[0002] Atopic dermatitis is a chronic inflammatory skin disease characterized by scaly rashes accompanied by itching. Atopic dermatitis is a multifactorial disease caused by the interaction of genetic factors, defects in barrier function, environmental factors, susceptibility to skin infections, and several immunological factors.

[0003] Atopic dermatitis is a very common disease in companion animals. Since dogs have a breed predisposition, genetic factors are considered very important. The most common symptom in dogs is the presence of skin itching due to constant scratching, licking, or rubbing.

[0004] Steroids, antihistamines, and antibiotics are often prescribed for the treatment of atopic dermatitis. Long-term use of these drugs may cause undesirable side effects. Therefore, it is necessary to find an effective and comfortable alternative treatment and its administration route for both companion animals and the humans treating them.

[0005] The topical route is used for the treatment of atopic dermatitis in companion animals, and this type of administration includes the administration of a topical solution (spot-on solution) with a pipette.

[0006] M. Blaskovic et al. (Vet. J. 199, 39-43 (2014)) disclose the use of a spot-on formulation containing polyunsaturated fatty acids and essential oils in dogs with atopic dermatitis. This product is administered once a week for 8 weeks.

[0007] R. Marsella et al. (BMC Vet. Res. 16, 92 (2020)) disclose the use of Atopivet Spot-on product in dogs with atopic dermatitis. This product is a topical solution in a pipette containing sphingolipids and glycosaminoglycans. One drop from one pipette is administered twice a week for 8 weeks to the following areas of the pet: ear, axilla, interdigital spaces of the fore and hind limbs, groin, chest, and back.

[0008] The product is expensive because it requires the use of 8 or 16 pipettes during spot-on treatment. It is also important to emphasize that having to frequently apply the product to various affected areas on the pet's body is inconvenient for both the dog and the owner.

[0009] Therefore, for the administration of active substances for atopic dermatitis, there is a need for an effective, easy-to-apply, cost-effective local route that does not require regular weekly application and releases the active substance over time, as an alternative to spot-on pipettes.

[0010] While collars for companion animals are widely used for topical administration of antiparasitic drugs (see, for example, patent GB2316871B), their use for administering active ingredients for atopic dermatitis has not been disclosed to date.

[0011] Even if insecticidal collars are effective, it is not clear that collars containing active ingredients for atopic dermatitis are effective. It cannot be ruled out that problems may occur, such as insufficient release of the active ingredient from the collar, or that the active ingredient does not spread throughout the animal's body before reaching the affected area. [Overview of the project]

[0012] The inventors have found that the collar of the present invention, as defined below, is novel, exhibits an appropriate in vitro kinetic release pattern of lipid extracts in adipose medium, and results in a significant reduction in lesions caused by atopic dermatitis at 4 and 8 weeks, and a significant reduction in skin itchiness at 4 and 8 weeks, in non-human animals, preferably companion animals. Therefore, it can be used for the treatment or prevention of atopic dermatitis or allergic dermatitis, as well as for restoring skin integrity during or after atopic dermatitis or allergic dermatitis, increasing skin hydration and flexibility, reducing skin itchiness, or promoting skin regeneration in non-human animals, preferably companion animals.

[0013] Thus, the present invention relates to a collar for non-human animals, preferably companion animals, comprising a polymer matrix and a lipid extract, wherein the lipid extract contains sphingomyelin.

[0014] In a preferred embodiment, the present invention relates to the previously defined collar, wherein the lipid extract is suitable for release into the body of a non-human animal, preferably a companion animal.

[0015] In another preferred embodiment, the present invention relates to the collar defined above, wherein the polymer matrix is ​​a thermoplastic polyurethane also known as TPU.

[0016] In another preferred embodiment, the present invention relates to the previously defined collar, wherein the lipid extract comprises at least 30% by weight of sphingomyelin relative to the total weight of the lipid extract.

[0017] In another preferred embodiment, the present invention relates to the previously defined collar, wherein the lipid extract comprises at least 45% by weight of sphingomyelin relative to the total weight of the lipid extract, and more preferably at least 50% by weight of sphingomyelin relative to the total weight of the lipid extract.

[0018] In another preferred embodiment, the present invention relates to the previously defined collar, wherein the lipid extract comprises 30% to 70% by weight of sphingomyelin, 1% to 15% by weight of ceramide, less than 0.5% by weight of sulfatide, less than 0.5% by weight of ganglioside, 20% to 58% by weight of phospholipids, and 0.5% to 10% by weight of neutral lipids, and the sum of the percentages of the lipid extract components is equal to 100%.

[0019] In a more preferred embodiment, the present invention relates to the previously defined collar, wherein the lipid extract comprises 45% to 65% by weight of sphingomyelin, 2% to 6% by weight of ceramide, less than 0.2% by weight of sulfatide, less than 0.2% by weight of ganglioside, 25% to 45% by weight of phospholipids, and 0.5% to 4.5% by weight of neutral lipids, and the sum of the percentages of the lipid extract components is equal to 100%.

[0020] In another preferred embodiment, the present invention relates to the previously defined collar, wherein the lipid extract comprises 50% to 59% by weight of sphingomyelin, 3.5% to 5.2% by weight of ceramide, less than 0.05% by weight of sulfatide, 0.05% by weight of ganglioside, 32% to 44% by weight of phospholipids, and 1% to 3% by weight of neutral lipids, and the sum of the percentages of the lipid extract components is equal to 100%.

[0021] The sphingomyelin group also includes dihydrosphingomyelin. The ceramide group includes ceramide, dihydroceramide, glucosylceramide, and lactosylceramide. Phospholipids include, for example, phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylserine, phosphatidylcholine plasmalogen, and lysophosphatidylethanolamine transformants. Neutral lipids include, for example, diacylglycerol and triacylglycerol. Lipid extracts have a very low sulfatide content, usually less than 0.5%, preferably less than 0.05%, and more preferably less than 0.01%. They also have a very low ganglioside (GM1, GM2, GM3, GD1) content, usually less than 0.5%, preferably less than 0.05%, and more preferably less than 0.01%. In fact, the sulfatide and ganglioside measurement method used was capable of detecting 0.006 mg / g of sulfatide and 0.009 mg / g of ganglioside, but the amounts of sulfatide and ganglioside were not detected in the three batches of lipid extracts used in this invention, as defined below.

[0022] In another preferred embodiment, the present invention relates to the collar as previously defined, wherein the lipid extract is of animal origin, preferably from cattle or pigs, more preferably from the intestinal mucosa of pigs or from the trachea of ​​cattle or pigs, and even more preferably from the trachea of ​​cattle.

[0023] In another preferred embodiment, the present invention relates to the previously defined collar, wherein the collar contains 2% to 5% by weight of a lipid extract relative to the weight of the collar, preferably 2% to 3% by weight of a lipid extract relative to the weight of the collar, and more preferably 2.5% by weight of a lipid extract relative to the weight of the collar.

[0024] In another preferred embodiment, the present invention relates to the collar defined above, wherein the polymer matrix and the lipid extract are present in the collar such that the weight ratio of the polymer matrix to the lipid extract is between 30:1 and 29:1, more preferably the ratio is 29.8:1 or 29.5:1.

[0025] In another preferred embodiment, the present invention relates to the collar defined above, and the collar is a dermatological collar.

[0026] The present invention also relates to a method for manufacturing a collar as defined above, comprising the following steps: 1) Heating the polymer matrix; 2) Adding a mixture containing a plasticizer and a stabilizer to the polymer matrix of step 1); 3) Cooling the mixture of step 2); 4) Adding the lipid extract; and 5) Shaping the mixture obtained in step 4) into the form of a collar.

[0027] In another embodiment, the present invention relates to a method for manufacturing the collar defined above, wherein the polymer matrix is thermoplastic polyurethane (TPU) and is preferably heated to a temperature between 90 °C and 95 °C.

[0028] In another embodiment, the present invention relates to a method for manufacturing the collar defined above, wherein the plasticizer is ethylhexyl diphenyl phosphate and the stabilizer is a mixture of C7-9-alkyl 3-(3,5-di-trans-butyl-4-hydroxyphenyl) propionate, 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol isomer, bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate, and methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate.

[0029] In another embodiment, the present invention relates to a method for obtaining the collar defined above, wherein a fragrance is added in step 2), preferably the fragrance is lavender oil.

[0030] In another embodiment, the present invention relates to a method for obtaining the previously defined collar, wherein in step 3), the mixture from step 2) is cooled to room temperature.

[0031] In another embodiment, the present invention relates to a method for obtaining the previously defined collar, wherein steps 1), 2), 3), and 4) are carried out under stirring.

[0032] In another embodiment, the present invention relates to a method for obtaining the previously defined collar, wherein the mixture obtained from step 4) is injection molded into the shape of a collar. Collars of different lengths, for example, 35 cm or 75 cm, can be obtained.

[0033] In another embodiment, the present invention relates to a method for obtaining the previously defined collar, wherein a dye such as black iron oxide is added in step 4.

[0034] In another embodiment, the present invention relates to a method for obtaining the previously defined collar, wherein the polymer matrix and lipid extract are present in the collar in a polymer matrix to lipid extract weight ratio between 30:1 and 29:1, more preferably 29.8:1 or 29.5:1.

[0035] The present invention also relates to the previously defined collar for use as a pharmaceutical.

[0036] The present invention also relates to the previously defined collar for use as an animal health product.

[0037] When the collar of the present invention is used as an animal health product, it will be understood that the collar is intended for the diagnosis, prevention, treatment, alleviation, or cure of diseases or illnesses in non-human animals.

[0038] The present invention also relates to the previously defined collar for use as an adjuvant.

[0039] When the collar of the present invention is used as an adjuvant, it will be understood that the collar containing the lipid extract complements or enhances the action of the active ingredient.

[0040] The present invention also relates to the previously defined collar for use in the treatment or prevention of atopic dermatitis or allergic dermatitis in non-human animals, preferably companion animals.

[0041] Similarly, the present invention also relates to the use of the previously defined collar for the manufacture of a medicament for the treatment or prevention of atopic dermatitis or allergic dermatitis in non-human animals, preferably companion animals.

[0042] Similarly, the present invention also relates to a method for treating or preventing atopic dermatitis or allergic dermatitis in a non-human animal, preferably a companion animal, which includes placing the previously defined collar around the neck of the animal.

[0043] The present invention also relates to a collar as defined above, for use in non-human animals, preferably companion animals, to restore skin integrity during or after atopic dermatitis or allergic dermatitis, to increase skin moisture and flexibility, to reduce skin itchiness, or to promote skin regeneration.

[0044] Similarly, the present invention also relates to the use of the previously defined collar in non-human animals, preferably companion animals, for restoring skin integrity during or after atopic dermatitis or allergic dermatitis, increasing skin moisture and flexibility, reducing skin itchiness, or promoting skin regeneration.

[0045] In another embodiment, the present invention relates to a collar for any of the uses defined above, characterized in that a lipid extract is released onto the body of a non-human animal by the collar being worn around the neck of an animal for eight weeks.

[0046] Throughout this invention, the term “animal” refers to a “non-human animal,” preferably a “companion animal.” Examples include, among others, dogs and cats. Preferably, the animal relating to this invention is a dog.

[0047] The present invention also relates to an animal health product in the form of a collar as defined above.

[0048] The lipid extract of the collar of the present invention can be obtained by extraction from mammalian tissues such as the intestinal mucosa of a pig or the trachea of ​​a cow or pig. Preferably, it can be obtained from the trachea of ​​a cow. The trachea is crushed and then subjected to enzymatic digestion in an aqueous medium (using a proteolytic enzyme, preferably subtilisin) at a temperature preferably between 50°C and 60°C, leaving a solid residue and an emulsion. Then, it is decanted at a temperature preferably between 80°C and 90°C, the solid residue is discarded, and the process is continued with the emulsion from which water has been removed by vacuum evaporation. Next, the concentrate obtained by evaporation is resuspended in acetone, preferably at a temperature of 30°C, diatomaceous earth is added, and it is filtered, and the insoluble fraction is resuspended in alcohol, preferably in methanol, at a temperature of 50°C. Next, this is filtered, the solid fraction is discarded, and the process is continued with the liquid fraction. Then, methanol is partially removed from the liquid fraction until a concentrate is obtained, and this is then precipitated with acetone. After decanting and removing the liquid fraction, the resulting solid fraction is washed several times with acetone if necessary, discarding the supernatant after each wash to retain the solid fraction, which is then vacuum-dried. Next, it is ground and sieved. This solid fraction constitutes a lipid extract containing sphingomyelin, which is used in the collar of the present invention. Various batches of lipid extract can be obtained according to this method, and their compositions can differ from one another (for example, see Table 1 for the compositions of three batches expressed as weight % of each component relative to the total weight of the lipid extract, where the sum of the percentages of lipid extract components is equal to 100%).

[0049] [Table 1]

[0050] Considering the variation in composition from batch to batch, the resulting lipid extract contains the group of compounds shown in Table 2.

[0051] [Table 2]

[0052] Preferably, the obtained lipid extract contains the group of compounds shown in Table 3.

[0053] [Table 3]

[0054] More preferably, the obtained lipid extract contains the group of compounds shown in Table 4.

[0055] [Table 4]

[0056] It should be noted that the lipid extract used in this invention contains sphingomyelin and is substantially free of sulfatides and gangliosides. For example, no sulfatides or gangliosides were detected in the three batches of lipid extracts shown in Table 1.

[0057] This collar has several advantages, in particular: - This allows for the effective temporal release of lipid extracts in adipose medium (corresponding to sebum derived from the skin of a companion animal), as can be seen in in vitro tests with releases at 8, 15, and 22 days (see Example 3).

[0058] - Efficacy has been demonstrated in dogs with atopic dermatitis, with a significant reduction in lesions and itching after 4 and 8 weeks (p<0.05) (see Example 4).

[0059] - At the mid-term stage of treatment (after 4 weeks), the treatment already showed excellent efficacy in reducing both lesions and itching. In fact, significant reductions were observed in the CADESI (Canine Atopic Dermatitis Extent and Severity Index) (lesions) (43%; p<0.05) and PICAD (Pruritus Index for Canine Atopic Dermatitis) (itching) (52.3%; p<0.05) from week 0 to week 4. Significant reductions (p<0.05) were also observed in the PVAS index (itching) from week 0 to week 2 (25.8%) and from week 1 to week 2 (20.6%). In contrast, with the Atopivet Spot-on pipette (R. Marsella et al., BMC Vet. Res. 16, 92 (2020)), the reduction in CADESI was only 5.1% after 4 weeks, which was not statistically significant, and therefore no effect was observed after 4 weeks based on the PVAS index. Thus, it can be said that the collar works faster for atopic dermatitis than Atopivet Spot-on.

[0060] - While the collar does not need to be combined with lipid extracts and glycosaminoglycans to be effective, the Atopivet Spot-on pipette requires that sphingolipids be combined with glycosaminoglycans.

[0061] - The treatment is easy and comfortable to administer. All that is required is to put a collar around the companion animal's neck and remove it after two months. With spot-on pipettes, creams, or gels, it is necessary to locate the lesion each time and apply the solution, cream, or gel from the pipette to the lesion.

[0062] - The frequency of product administration will decrease. The collar will be worn once every two months, but for example, with a Spot-on pipette, it will be applied once a week for 8 weeks, or twice a week for 8 weeks (16 times in total), as with an Atopivet Spot-on pipette.

[0063] - It is more cost-effective than spot-on pipettes and reduces the burden on companion animal caregivers. For example, compared to Atopivet spot-on pipettes, monthly costs can be saved by approximately 50%.

[0064] - No special care is required for pets before or after putting on a collar. On the other hand, with spot-on pipettes, it is recommended to wash the pet before each application and immediately after applying the pipette to avoid removing the product from the skin.

[0065] Throughout this specification and the claims, the phrase “comprises” and its variations are not intended to exclude other technical features, additives, components, or processes. Therefore, the term “comprises” should be understood to include “consists solely of” and “consists essentially of.”

[0066] To those skilled in the art, other objects, advantages, and features of the present invention can be partially inferred from both the description and embodiments of the invention. The following examples and figures are provided for illustrative purposes only and are not intended to limit the invention. [Brief explanation of the drawing]

[0067] [Figure 1] This shows the daily release percentage of lipid extracts in in vitro tests. [Figure 2] The mean score of the lesion using CADESI is shown at the start of treatment, 4 weeks later, and 8 weeks later. [Figure 3] The average itch severity score using PICAD is shown at the start of treatment, 4 weeks later, and 8 weeks later. [Figure 4] This shows the average score of itchiness severity using the PVAS index, as reported by dog ​​owners, at the start of treatment, one week after treatment, and two weeks after treatment. [Examples]

[0068] The following embodiments are for illustrative purposes only and do not limit the scope of the present invention.

[0069] Example 1: Making a collar with a length of 35 cm 9.76 g of thermoplastic polyurethane (TPU) was introduced into a reactor preheated to 90°C-95°C under stirring. Once the polymer reached the aforementioned temperature, 2.62 g of ethylhexyl diphenyl phosphate plasticizer, 0.0655 g of a mixture of C7-9-alkyl 3-(3,5-di-trans-butyl-4-hydroxyphenyl)propionate, 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol isomer, bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate stabilizers, and 0.1965 g of lavender oil were gradually added. Stirring was continued until the mixture was completely incorporated into the polymer. The resulting mixture was then cooled to room temperature while maintaining constant stirring. Subsequently, 0.33 g of lipid extract was added (see composition in Table 4), the resulting mixture was stained (with black iron oxide) and homogenized. The reactor was drained, and the final mixture was injection molded in a mold. The resulting collars contained 2.5% by weight of lipid extract relative to the weight of the collar.

[0070] Example 2: Making a collar with a length of 75 cm The same method as described for the 35cm collar was repeated, but in this case, 19.67g of thermoplastic polyurethane, 0.66g of lipid extract, 5.28g of ethylhexyl diphenyl phosphate plasticizer, 0.132g of C7-9-alkyl 3-(3,5-di-trans-butyl-4-hydroxyphenyl)propionate, a mixture of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol isomers, bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate stabilizers, and 0.396g of lavender oil were used. The resulting collar contained 2.5% by weight of lipid extract relative to the weight of the collar.

[0071] Example 3: In vitro test on the release of lipid extracts The purpose of this study was to evaluate in vitro how much lipid extract is released from the collar and for how long in a lipid medium, which is considered representative of sebum from livestock skin.

[0072] Materials and methods This test was performed using laboratory batches of three collars containing 2.5% by weight of lipid extract, obtained according to Example 1.

[0073] Three collars were fragmented, and each collar fragment was immersed in a lipid medium consisting of a triglyceride mixture and shaken with a magnetic stirrer. A sample of each collar fragment was taken at the start of the analysis, and at 8, 15, and 22 days later. At each of these time points, the same laboratory analysis was performed: quantification of methyl palmitate (a component of the lipid extract) by gas chromatography. This allowed us to determine the amount of lipid extract remaining in each of the three collars and calculate the average value for the three collars. The percentage of release was measured using this value.

[0074] result The results obtained are summarized in Table 5 below:

[0075] [Table 5]

[0076] Figure 1 also shows the percentage of lipid extract release over time.

[0077] As observed, the release percentage of the lipid extract after 22 days was 21% of the triglyceride mixture. Therefore, this study demonstrated good release kinetics of the lipid extract in the lipid medium.

[0078] Example 4: In vivo study of efficacy and safety in dogs with atopic dermatitis The purpose of this study was to measure the effectiveness of collar application in the management of canine patients with atopic dermatitis, and to evaluate the safety of product application, the extent and severity of lesions, and the effect on itching.

[0079] Materials and methods This study included 12 dogs of different breeds, sexes, and ages that had been definitively diagnosed with non-seasonal atopic dermatitis and had no other serious comorbidities. Depending on the size of the dog, they were fitted with either the collar from Example 1 or Example 2.

[0080] The total treatment and follow-up period from the start of treatment was 8 weeks. Veterinary control visits were conducted at the start of treatment (week 0), 4 weeks, and 8 weeks, using two scores (Canine Atopic Dermatitis Extent and Severity Index - CADESI)-4 and the Pruritus Index for Canine Atopic Dermatitis - PICAD), in addition to weekly itching assessments by the owner (Pruritus Visual Analog Scale - PVAS).

[0081] CADESI made it possible to score various lesions (erythema, lichenification, alopecia / abrasion) in various parts of the body (pinna, armpit, forelegs and hind legs, elbow creases, carpal and palmar pads, flanks, groin, lower abdomen, perineum, and ventral proximal part of the tail).

[0082] PICAD makes it possible to score itching in various parts of the body by observing the following frequency and intensity: scratching / shaking the ears, scratching / rubbing the head, scratching / rubbing / licking the trunk and armpits, scratching / rubbing / licking the abdomen, licking / biting the forelegs, licking / biting the hind legs, licking / biting the legs, and rubbing / licking / biting the anal genital area.

[0083] The PVAS index allows for the scoring of itching observed by dog ​​owners. Owners rate the degree of itching their pets exhibit once a week on a scale of 0 to 10, where 0 represents no itching and 10 represents unbearable itching.

[0084] result The collar was deemed safe to wear for 8 weeks, and no related side effects occurred.

[0085] In addition to a significant decrease (43%; p<0.05) observed between weeks 0 and 4, CADESI also showed a significant decrease (48.6%; p<0.05) between weeks 0 and 8 (see Figure 2).

[0086] In PICAD, a significant decrease was observed from week 0 to week 4 (52.3%; p<0.05) and from week 0 to week 8 (43.2%; p<0.05) (see Figure 3).

[0087] A significant decrease (p<0.05) in the PVAS index was observed between 0 and 2 weeks (25.8%) and between 1 and 2 weeks (20.6%) (see Figure 4).

Claims

1. A collar for non-human animals comprising a polymer matrix and a lipid extract, wherein the lipid extract comprises sphingomyelin, The polymer matrix is ​​thermoplastic polyurethane. A collar characterized by the following features.

2. The collar according to claim 1, wherein the lipid extract contains at least 30% by weight of sphingomyelin relative to the total weight of the lipid extract.

3. The collar according to claim 2, wherein the lipid extract contains 30% to 70% by weight of sphingomyelin, 1% to 15% by weight of ceramide, less than 0.5% by weight of sulfatide, less than 0.5% by weight of ganglioside, 20% to 58% by weight of phospholipids, and 0.5% to 10% by weight of neutral lipids, and the sum of the percentages of the components of the lipid extract is equal to 100%.

4. The collar according to claim 3, wherein the lipid extract contains 45% to 65% by weight of sphingomyelin, 2% to 6% by weight of ceramide, less than 0.2% by weight of sulfatide, less than 0.2% by weight of ganglioside, 25% to 45% by weight of phospholipids, and 0.5% to 4.5% by weight of neutral lipids, and the sum of the percentages of the components of the lipid extract is equal to 100%.

5. The collar according to claim 4, wherein the lipid extract contains 50% to 59% by weight of sphingomyelin, 3.5% to 5.2% by weight of ceramide, less than 0.05% by weight of sulfatide, less than 0.05% by weight of ganglioside, 32% to 44% by weight of phospholipids, and 1% to 3% by weight of neutral lipids, and the sum of the percentages of the components of the lipid extract is equal to 100%.

6. The collar according to claim 1, wherein the lipid extract is from a cow or a pig.

7. The collar according to claim 6, wherein the lipid extract is derived from the trachea of ​​a cow or a pig.

8. The collar according to claim 1, comprising 2% to 5% by weight of the lipid extract relative to the weight of the collar.

9. The collar according to claim 8, comprising 2.5% by weight of the lipid extract relative to the weight of the collar.

10. A collar according to claim 1, for use as a pharmaceutical product.

11. The collar according to claim 1, wherein the lipid extract functions as an adjuvant.

12. The collar according to claim 1, for use in the treatment or prevention of atopic dermatitis or allergic dermatitis in non-human animals.

13. The collar according to claim 1, for use in non-human animals to restore skin integrity during or after atopic dermatitis or allergic dermatitis, to increase skin moisture and flexibility, to reduce skin itchiness, or to promote skin regeneration.

14. A collar for use according to any one of claims 10 to 13, characterized in that the lipid extract is released onto the body of the non-human animal by being worn around the neck of the non-human animal for eight weeks.

Images